For research use only. Not for therapeutic Use.
Sodium metatungstate (Sodium polyoxotungstate) is a NTPDase inhibitor, with Ki values of 2.58 μM, 3.26 μM, and 28.8 μM for NTPDase 1 (CD39), NTPDase 3 and NTPDase 2 respectively[1]. Sodium metatungstate has anti-inflammatory and anti-cancer effect. Sodium metatungstate inhibits ATP breakdown but also blocks central synaptic transmission[1][2][3][4].
Sodium metatungstate (100 μM, 15 min) inhibits the ATP-induced uptake of anionic dyes and the large ATP-induced channels in macrophage[2].
Sodium metatungstate (100 μM, 8 h) inhibits ATP-induced P2X7-associated pyroptosis in macrophage[2].
Sodium metatungstate (100 μM, 8-24 h) has a potent anti-inflammatory effect on macrophages[2].
Sodium metatungstate (5 mg/kg, Intraperitoneal injection, single dose) shows different cytokine/chemokine responses in the peritoneum and systemically in the bloodstream in CD39 knockout mice[3].
Sodium metatungstate (5 mg/kg, Intraperitoneal injection, once per day from 0 to day 4, day 7-11, and day 14-18.) combine with anti-CD73 antibody and AZD4635(HY-101980) reduces tumor load in multiple myeloma (MM) mice[4].
| Catalog Number | R014589 |
| CAS Number | 12141-67-2 |
| Molecular Formula | H2Na6O40W12 |
| Purity | ≥95% |
| Reference | [1]. Wall M J, et al. The novel NTPDase inhibitor sodium polyoxotungstate (POM-1) inhibits ATP breakdown but also blocks central synaptic transmission, an action independent of NTPDase inhibition [J]. Neuropharmacology, 2008, 55(7): 1251-1258. [2]. Pimenta-dos-Reis G, et al. POM-1 inhibits P2 receptors and exhibits anti-inflammatory effects in macrophages [J]. Purinergic Signalling, 2017, 13: 611-627. [3]. Csóka B, et al. CD39 improves survival in microbial sepsis by attenuating systemic inflammation [J]. The FASEB Journal, 2015, 29(1): 25. [4]. Yang R, et al. Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade [J]. Journal for immunotherapy of cancer, 2020, 8(1). |
